Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.54 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.54 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.54 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.49 |
| ▸ | ALB | P02768 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.49 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.49 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.49 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.48 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19717860 | 1.00 | POLB (0.67) | POLBP2RY2P2RY4P2RY6PDE3A | |
| SCHEMBL5666385 | 0.89 | POLB (0.68) | POLBP2RY2P2RY4P2RY6PDE3A | |
| SCHEMBL1939479 | 0.89 | POLB (0.68) | POLBP2RY2P2RY4P2RY6PDE3A | |
| SCHEMBL3424606 | 0.89 | POLB (0.68) | POLBP2RY2P2RY4P2RY6PDE3A | |
| SCHEMBL15617962 | 0.89 | POLB (0.68) | POLBP2RY2P2RY4P2RY6PDE3A | |
| SCHEMBL3200090 | 0.89 | POLB (0.68) | POLBP2RY2P2RY4P2RY6PDE3A | |
| SCHEMBL25456568 | 0.88 | POLB (0.67) | POLBP2RY2P2RY4P2RY6PDE3A | |
| SCHEMBL16359976 | 0.88 | POLB (0.67) | POLBP2RY2P2RY4P2RY6PDE3A | |
| SCHEMBL15798554 | 0.88 | POLB (0.67) | POLBP2RY2P2RY4P2RY6PDE3A | |
| SCHEMBL992473 | 0.88 | POLB (0.67) | POLBP2RY2P2RY4P2RY6PDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470522-B2 | Three-dimensional culture containing human articular chondrocytes with induced terminal differentiation changes and preparation process and uses of the same | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2013-06-25 | — | — | US | claimed |
| EP-2207786-A1 | 2 ' -FLU0R0-2 ' -DEOXYTETRAHYDROURIDINES AS CYTIDINE DEAMINASE INHIBITORS | Eisai Inc. (US) | 2010-07-21 | — | — | EP | claimed |
| US-20090137521-A1 | Certain Compounds, Compositions and Methods | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2009-05-28 | — | — | US | claimed |
| WO-2009052287-A1 | 2 ' -FLU0R0-2 ' -DEOXYTETRAHYDROURIDINES AS CYTIDINE DEAMINASE INHIBITORS | EISAL CORPORATION OF NORTH AMERICA (US) | 2009-04-23 | — | — | WO | claimed |
| US-20230270771-A1 | LOW DOSE COMBINATION CDA SUBSTRATE DRUG/CEDAZURIDINE WITH EXTENDED ADMINISTRATION | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-08-31 | — | — | US | disclosed |
| US-11660310-B2 | Low dose combination CDA substrate drug/cedazuridine with extended administration | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-05-30 | — | — | US | disclosed |
| US-20220110958-A1 | LOW DOSE COMBINATION CDA SUBSTRATE DRUG/CEDAZURIDINE WITH EXTENDED ADMINISTRATION | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2022-04-14 | — | — | US | disclosed |
| US-11224610-B2 | Low dose combination CDA substrate drug/cedazuridine with extended administration | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-01-18 | — | — | US | disclosed |
| US-20200085848-A1 | LOW DOSE COMBINATION CDA SUBSTRATE DRUG/CEDAZURIDINE WITH EXTENDED ADMINISTRATION | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-03-19 | — | — | US | disclosed |
| US-9567363-B2 | Certain compounds, compositions and methods | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-02-14 | — | — | US | disclosed |
| EP-2447272-B1 | 2'-FLUORO-2'-DEOXYTETRAHYDROURIDINES AS CYTIDINE DEAMINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2017-02-01 | — | — | EP | disclosed |
| US-20150210730-A1 | CERTAIN COMPOUNDS, COMPOSITIONS AND METHODS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-07-30 | — | — | US | disclosed |
| US-20120289475-A1 | Certain Compounds, Compositions and Methods | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2012-11-15 | — | — | US | disclosed |
| US-8268800-B2 | Certain compounds, compositions and methods | EISAI INC. (US) | 2012-09-18 | — | — | US | disclosed |
| EP-2447272-A1 | 2'-Fluoro-2'-deoxytetrahydrouridines as cytidine deaminase inhibitors | Eisai Inc. (US) | 2012-05-02 | — | — | EP | disclosed |
| EP-2207786-B1 | 2'-FLUORO-2'-DEOXYTETRAHYDROURIDINES AS CYTIDINE DEAMINASE INHIBITORS | EISAI INC (US) | 2012-03-07 | — | — | EP | disclosed |
| EP-2207786-A1 | 2 ' -FLU0R0-2 ' -DEOXYTETRAHYDROURIDINES AS CYTIDINE DEAMINASE INHIBITORS | Eisai Inc. (US) | 2010-07-21 | — | — | EP | disclosed |
| US-20090137521-A1 | Certain Compounds, Compositions and Methods | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2009-05-28 | — | — | US | disclosed |
| WO-2009052287-A1 | 2 ' -FLU0R0-2 ' -DEOXYTETRAHYDROURIDINES AS CYTIDINE DEAMINASE INHIBITORS | EISAL CORPORATION OF NORTH AMERICA (US) | 2009-04-23 | — | — | WO | disclosed |
| US-5530110-A | 4-ethoxy-5-fluoro-2'-deoxyuridine | CITY OF HOPE (US) | 1996-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11224610-B2 | Low dose combination CDA substrate drug/cedazuridine with extended administration | CDA, DNMT1, DUT | POLB 224/4885P2RY2 2848/4885P2RY4 3138/4885 |
| US-20150210730-A1 | CERTAIN COMPOUNDS, COMPOSITIONS AND METHODS | DUT, TYMP, DPYD | POLB 123/4885P2RY2 1144/4885P2RY4 676/4885 |
| US-20200085848-A1 | LOW DOSE COMBINATION CDA SUBSTRATE DRUG/CEDAZURIDINE WITH EXTENDED ADMINISTRATION | CDA, DNMT1, DUT | POLB 224/4885P2RY2 2848/4885P2RY4 3138/4885 |
| US-20090137521-A1 | Certain Compounds, Compositions and Methods | DUT, TYMP, DPYD | POLB 123/4885P2RY2 1144/4885P2RY4 676/4885 |
| US-20230270771-A1 | LOW DOSE COMBINATION CDA SUBSTRATE DRUG/CEDAZURIDINE WITH EXTENDED ADMINISTRATION | CDA, DNMT1, DUT | POLB 224/4885P2RY2 2848/4885P2RY4 3138/4885 |
| US-20220110958-A1 | LOW DOSE COMBINATION CDA SUBSTRATE DRUG/CEDAZURIDINE WITH EXTENDED ADMINISTRATION | CDA, DNMT1, DUT | POLB 224/4885P2RY2 2848/4885P2RY4 3138/4885 |
| US-20120289475-A1 | Certain Compounds, Compositions and Methods | DUT, TYMP, DPYD | POLB 123/4885P2RY2 1144/4885P2RY4 676/4885 |
| US-11660310-B2 | Low dose combination CDA substrate drug/cedazuridine with extended administration | CDA, DNMT1, DUT | POLB 224/4885P2RY2 2848/4885P2RY4 3138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.